Pharmacogenetic interactions in amyotrophic lateral sclerosis: a step closer to a cure?

Randomization in Clinical Trials

(2018) Kristine Broglio   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Increasing the efficiency of clinical trials in neurodegenerative disorders using group sequential trial designs

(2018) Ruben P.A. van Eijk et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model

(2018) Henk-Jan Westeneng et al.   LANCET NEUROLOGY

Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressiveSOD1ALS

(2018) Michael Benatar et al.   NEUROLOGY

Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials

(2017) Ruben P A van Eijk et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Amyotrophic lateral sclerosis

(2017) Michael A van Es et al.   LANCET

Drug therapy: On the treatment trail for ALS

(2017) Andrew Scott   NATURE

Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials

(2017) Ruben P.A. van Eijk et al.   NEUROLOGY

Pathogenic determinants and mechanisms of ALS/FTD linked to hexanucleotide repeat expansions in the C9orf72 gene

(2017) Xinmei Wen et al.   NEUROSCIENCE LETTERS

Amyotrophic Lateral Sclerosis

(2017) Robert H. Brown et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis

(2016) Wouter van Rheenen et al.   NATURE GENETICS

A blinded international study on the reliability of genetic testing for GGGGCC-repeat expansions inC9orf72reveals marked differences in results among 14 laboratories

(2014) Chizuru Akimoto et al.   JOURNAL OF MEDICAL GENETICS

Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?

(2014) Hiroshi Mitsumoto et al.   LANCET NEUROLOGY

Genetic heterogeneity of amyotrophic lateral sclerosis: Implications for clinical practice and research

(2014) Xiaowei W. Su et al.   MUSCLE & NERVE

The risks and rewards of covariate adjustment in randomized trials: an assessment of 12 outcomes from 8 studies

(2014) Brennan C Kahan et al.   Trials

ALS mutant FUS disrupts nuclear localization and sequesters wild-type FUS within cytoplasmic stress granules

(2013) Caroline Vance et al.   HUMAN MOLECULAR GENETICS

An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study

(2013) Timothy M Miller et al.   LANCET NEUROLOGY

Treatment Heterogeneity and Individual Qualitative Interaction

(2012) Robert S. Poulson et al.   AMERICAN STATISTICIAN

Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72

(2012) A. Chio et al.   BRAIN

Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72

(2012) Johnathan Cooper-Knock et al.   BRAIN

Potential of adaptive clinical trial designs in pharmacogenetic research

(2012) Frederieke H van der Baan et al.   PHARMACOGENOMICS

Pyrimethamine decreases levels of SOD1 in leukocytes and cerebrospinal fluid of ALS patients: A phase I pilot study

(2012) Dale J. Lange et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS

(2011) Mariely DeJesus-Hernandez et al.   NEURON

A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD

(2011) Alan E. Renton et al.   NEURON

Statistical considerations in evaluating pharmacogenomics-based clinical effect for confirmatory trials

(2010) Sue-Jane Wang et al.   Clinical Trials

Analysis ofFGGYas a risk factor for sporadic amyotrophic lateral sclerosis

(2009) Michael A. Van Es et al.   Amyotrophic Lateral Sclerosis

Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis

(2009) Sanne Piepers et al.   ANNALS OF NEUROLOGY

Large-scale SOD1 mutation screening provides evidence for genetic heterogeneity in amyotrophic lateral sclerosis

(2009) M. A. van Es et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Utility of Adaptive Strategy and Adaptive Design for Biomarker-facilitated Patient Selection in Pharmacogenomic or Pharmacogenetic Clinical Development Program

(2009) Sue-Jane Wang   JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION

Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis

(2009) Michael A van Es et al.   NATURE GENETICS

Prevalence of SOD1 mutations in the Italian ALS population

(2008) A. Chio et al.   NEUROLOGY